Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 1

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 1
---
 of current portion 
     238,942  
     342,098 
  
    Finance lease liability, net of current portion 
     1,998  
     444,448 
  
    Notes payable, net of current portion 
     43,658  
     20,180 

    Total liabilities 
     2,644,171  
     3,911,631 

    Commitments and contingencies (Note 11) 
     -  
     - 

    Stockholders’ equity: 

    Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; 700 and 0 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively 
     1  
     — 
  
    Common Stock, par value $0.007 per share; 350,000,000 shares authorized; 3,466,260 and 507,520 issued and outstanding at September 30, 2025, and December 31, 2024, respectively(1) 
     24,264  
     3,553 
  
    Additional paid-in capital(1) 
     74,294,531  
     56,242,793 
  
    Accumulated deficit 
     (65,416,598) 
     (53,644,310)

    Total stockholders’ equity 
     8,902,198  
     2,602,036 

    Total liabilities and stockholders’
equity 
    $11,546,369  
    $6,513,667 

(1)The
                                            values of Common Stock and paid-in capital, as well as the number of shares issued and outstanding,
                                            have been retroactively adjusted in order to give effect to the Company’s 1-for-30
                                            reverse stock split.

The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

bioAffinity
Technologies, Inc.

Unaudited
Condensed Consolidated Statements of Operations

    2025  
    2024  
    2025  
    2024 

    Three Months Ended  September 30,  
    Nine Months Ended  September 30, 

    2025  
    2024  
    202